Sanofi vs Galapagos NV: SG&A Expense Trends

SG&A Expense Trends: Sanofi vs Galapagos NV

In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Sanofi and Galapagos NV from 2014 to 2023. Sanofi, a global leader, consistently allocated a significant portion of its budget to SG&A, with expenses peaking at approximately €10.8 billion in 2023. This represents a steady increase of around 26% over the decade, reflecting its expansive market strategies.

Conversely, Galapagos NV, a smaller biotech firm, exhibited a more volatile SG&A trend. Starting at €9 million in 2014, their expenses surged to €239 million by 2022, marking an astonishing growth of over 2500%. This dramatic rise underscores Galapagos NV's aggressive expansion and investment in market presence. The contrasting strategies of these companies highlight the diverse approaches within the pharmaceutical sector.